Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huo Xue Chang Zhi is a Traditional Chinese Medicine (TCM) herbal formulation, typically administered as granules, specifically developed for the treatment of post-stroke depression (PSD). The formula is designed based on the TCM principles of "invigorating blood to remove stasis" (Huo Xue) and "soothing the liver to relieve depression" (Chang Zhi), addressing the dual pathology of blood stasis and Qi stagnation common in stroke survivors. Clinical research, primarily led by institutions in China, suggests that the formula may improve depressive symptoms and neurological recovery by modulating monoamine neurotransmitters and increasing the expression of neurotrophic factors. It is often studied as an alternative or adjunctive therapy to conventional antidepressants like SSRIs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huo xue chang zhi.